KR20170131963A - A composition comprising extracts of Terminalia chebula or compounds isolated from the above extracts for decreasing uric acid concentration in blood - Google Patents
A composition comprising extracts of Terminalia chebula or compounds isolated from the above extracts for decreasing uric acid concentration in blood Download PDFInfo
- Publication number
- KR20170131963A KR20170131963A KR1020160062829A KR20160062829A KR20170131963A KR 20170131963 A KR20170131963 A KR 20170131963A KR 1020160062829 A KR1020160062829 A KR 1020160062829A KR 20160062829 A KR20160062829 A KR 20160062829A KR 20170131963 A KR20170131963 A KR 20170131963A
- Authority
- KR
- South Korea
- Prior art keywords
- uric acid
- extract
- composition
- blood
- extracts
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 43
- 150000001875 compounds Chemical class 0.000 title claims abstract description 15
- 239000000203 mixture Substances 0.000 title claims abstract description 15
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title abstract description 45
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title abstract description 44
- 229940116269 uric acid Drugs 0.000 title abstract description 44
- 210000004369 blood Anatomy 0.000 title abstract description 21
- 239000008280 blood Substances 0.000 title abstract description 21
- 241000001522 Terminalia chebula Species 0.000 title abstract description 3
- 235000011517 Terminalia chebula Nutrition 0.000 title abstract description 3
- 230000003247 decreasing effect Effects 0.000 title description 5
- 201000005569 Gout Diseases 0.000 claims abstract description 21
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 201000001431 Hyperuricemia Diseases 0.000 claims description 9
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 235000004515 gallic acid Nutrition 0.000 claims description 3
- 229940074391 gallic acid Drugs 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 108010093894 Xanthine oxidase Proteins 0.000 abstract description 12
- 102100033220 Xanthine oxidase Human genes 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 8
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 230000001747 exhibiting effect Effects 0.000 abstract description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 10
- 241001572175 Gaza Species 0.000 description 9
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000013078 crystal Substances 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 6
- 206010003246 arthritis Diseases 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 5
- 229960003459 allopurinol Drugs 0.000 description 5
- 229950000193 oteracil Drugs 0.000 description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 206010018634 Gouty Arthritis Diseases 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 239000000401 methanolic extract Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229940075420 xanthine Drugs 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010021024 Hypolipidaemia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010029148 Nephrolithiasis Diseases 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 208000026816 acute arthritis Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
- 229960003081 probenecid Drugs 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- NTDFJPCHHGBHCO-UHFFFAOYSA-N 7,9-dihydro-3H-purine-2,6,8-trione Chemical compound OC1=NC(O)=C2NC(O)=NC2=N1.N1C(=O)NC(=O)C2=C1NC(=O)N2 NTDFJPCHHGBHCO-UHFFFAOYSA-N 0.000 description 1
- WVLFZLFLLJQWOR-UHFFFAOYSA-N 7,9-dihydro-3h-purine-2,6,8-trione;potassium Chemical compound [K].N1C(=O)NC(=O)C2=C1NC(=O)N2 WVLFZLFLLJQWOR-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- HGJXAVROWQLCTP-YABCKIEDSA-N Chebulagic acid Chemical compound O([C@H]1[C@H]2[C@H]3OC(=O)C4=CC(O)=C(O)C(O)=C4C4=C(O)C(O)=C(O)C=C4C(=O)OC[C@@H](O1)[C@H]3OC(=O)[C@@H](CC(O)=O)[C@@H]1[C@@H](C(OC=3C(O)=C(O)C=C(C1=3)C(=O)O2)=O)O)C(=O)C1=CC(O)=C(O)C(O)=C1 HGJXAVROWQLCTP-YABCKIEDSA-N 0.000 description 1
- 229920002052 Chebulagic acid Polymers 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000002034 butanolic fraction Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- UGIVASYMZSZAMP-UHFFFAOYSA-N chebulagic acid Natural products OC1C2c3c(OC1=O)c(O)c(O)cc3C(=O)OC4C(OC(=O)c5cc(O)c(O)c(O)c5)OC6COC(=O)c7cc(O)c(O)c(O)c7c8c(O)c(O)c(O)cc8C(=O)OC4C6OC(=O)C2(O)C(=O)O UGIVASYMZSZAMP-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- -1 superoxide radicals Chemical class 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 150000007968 uric acids Chemical class 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
Abstract
Description
본 발명은 가자 추출물 또는 이로부터 분리된 화합물을 유효성분으로 포함하는 혈 중 요산 감소 조성물을 제공한다. 본 발명의 조성물에 포함된 유효성분은 잔틴산화효소(Xanthine oxidase) 저해를 통해 혈 중의 요산을 감소시켜 고요산혈증 및 통풍 개선 효과를 나타낸다.The present invention provides a composition for reducing uric acid in blood, comprising as an active ingredient a Ghazu extract or a compound isolated therefrom. The active ingredient contained in the composition of the present invention reduces uric acid in the blood through inhibition of xanthine oxidase, thereby exhibiting hyperlipidemia and gout improvement.
가자는 사군자과의 가자나무(Terminalia chebula Retzius)의 익은 열매를 말린 것이다. 알려진 화학 성분으로는 갈릭산(galic acid), 탄닌 및 엘라직산 (ellagic acid) 등이 있다. 가자에는 탄닌이 비교적 많이 함유되어 있어 수렴(收斂), 지사(止瀉)작용이 있고, 가자 추출물이 항균활성 및 항진균활성을 나타낸다는 보고가 있다. 최근에는 가자 추출물로부터 분리된 체불락산(chebulagic acid)의 관절염 또는 염증에 대한 효과가 연구되고 있다(Lee SI et al., Arthritis Rheum., 52: 345-353, 2005; Reddy DB et al., Biochem. Biophys. Res. Commun., 381: 112-117, 2009).The Gaza is the Gaza Strip ( Terminalia chebula Retzius ) is dried. Known chemical components include galic acid, tannin, and ellagic acid. It has been reported that GAZA has a relatively high content of tannin and has convergence and antidiarrheal activity. GADA extract has antimicrobial activity and antifungal activity. In recent years, the effects of chebulagic acid isolated from Gadja extract on arthritis or inflammation have been studied (Lee SI et al., Arthritis Rheum., 52: 345-353, 2005; Reddy DB et al., Biochem Biophys. Res Commun., 381: 112-117, 2009).
요산이 생성되는 경로는 크게 외재성 요산(섭취한 음식물에 포함된 퓨린체에서 유래)과 내재성 요산(신체에서 파괴되는 세포에서 유래)으로 구분될 수 있다. 이렇게 만들어진 요산의 대부분은 신장에서 복잡한 과정을 거쳐서 소변으로 배출되는데, 생산과 배출의 균형이 깨어지면 문제가 발생한다. 정상 남성의 경우 혈중 요산농도는 7~8 mg/dL 이하, 정상 여성의 경우 혈중 요산농도는 6 mg/dL 이하이다. The pathway through which uric acid is produced can be broadly divided into extrinsic uric acid (derived from the purine body contained in the ingested food) and endogenous uric acid (derived from cells destroyed in the body). Most of this uric acid is excreted in the urine through the intestines in a complicated process. Problems arise when the balance between production and discharge is broken. Normal men have a uric acid concentration of 7 to 8 mg / dL or less, and normal women have a uric acid concentration of 6 mg / dL or less.
혈중 요산치는 개인차가 있지만 9 mg/dL을 초과하면 통증이 나타나며 심장이나 신장, 뇌의 혈관장애를 일으킬 위험이 있고, 10 mg/dL 이상이면 발작이 일어난다. 통풍은 관절염이 가장 흔한 증상이지만, 급성 또는 만성적으로 신기능의 저하를 초래할 수도 있다.There are individual differences in serum uric acid levels, but if it exceeds 9 mg / dL, the pain may be present and may lead to heart, kidney, and brain vascular disorders, and if it is 10 mg / dL or more, seizures may occur. Gout is the most common symptom of arthritis, but may cause acute or chronic decline in renal function.
통풍(Gout)은 혈액 중에 요산이 높은 상태로 오래 지속되어 형성되는 요산의 결정체가 몸 밖으로 배출되지 못하고, 여러 조직에 쌓여 다양한 증상을 유발하는 대사성 질환이다. 혈중 요산이 증가하는 경우는 과도한 요산의 생산과 신장을 통한 배설 과정의 이상 때문에 제대로 배출되지 못해서 나타날 수 있다. 혈중 요산 수치가 높다고 해서 바로 통풍으로 발병하는 것은 아니고, 높은 요산 수치에 의해 요산 결정체가 쉽게 형성되어 여러 조직에 침착된 상태가 10~20년간 지속되면 유발 인자에 의해 통풍을 일으키게 된다. 이는 주로 40~50대 남성에서 흔하지만 식생활 변화 및 환경변화에 따라 발병 연령이 점점 낮아지고 있으며, 여성은 폐경기 이후 혹은 장기이식 수술 후 면역저해제를 장기 복용하거나 이뇨제의 장기 복용으로 신기능이 저하된 여성에게서 발병할 가능성이 높다.Gout is a metabolic disease in which the crystals of uric acid, which are formed by a long period of high uric acid in the blood, can not be discharged out of the body and accumulate in various tissues and cause various symptoms. Increased serum uric acid can be caused by excessive uric acid production and poor excretion through excretion. High uric acid levels are not caused by gout, but uric acid crystals are easily formed by high uric acid levels and are deposited in various tissues for 10 to 20 years. Although it is common in men in their 40s and 50s, the age at onset is gradually decreasing with changes in dietary life and environment. Women are women who have had a long-term use of immunosuppressants after menopause or after organ transplantation, The possibility of developing the disease is high.
이와 같은 통풍의 원인을 살펴보면, 우리 몸을 구성하고 있는 대부분의 세포는 핵을 가지고 있는데, 이는 유전정보를 담고 있는 핵산으로 이루어져 있다. 핵산은 퓨린(purine)이나 피리미딘(pyrimidine)으로 구성되어 있고, 세포 수명이 다하면 파괴되어 핵 속의 퓨린체가 분해되어 요산(uric acid)이 대량 만들어지고, 요산나트륨의 결정이 조직에 침착함으로써 염증을 일으키는 질병으로 고요산혈증, 통풍성 관절염, 통풍성 신질환, 통풍성 신결석증 등을 일으키게 된다고 알려져 있다(Yagi K et al., Chem. Phys. Lipids, 45: 337-351, 1987).The cause of this gout is that most of the cells that make up our body have nuclei, which are made up of nucleic acids that contain genetic information. The nucleic acid is composed of purine or pyrimidine. When the cell life is over, the nucleic acid is destroyed and the purine body in the nucleus is decomposed to produce a large amount of uric acid. The crystal of sodium urate precipitates in the tissue, (Yagi K et al., Chem. Phys. Lipids, 45: 337-351, 1987), which are known to cause hyperuricemia, gouty arthritis, gouty renal disease and gouty nephrolithiasis.
통풍 치료 시 콜치신(colchicine, 진단이 확실하지 않은 경우에 사용), 비스테로이드 항염제(합병증이 없고 진단이 확실한 경우에 사용하나 소화성 궤양, 신기능 장애, 부종 악화 등의 부작용 가능성이 많음), 스테로이드(단발성 관절염에서 관절강 내 주사나 근육주사로 사용)를 주로 사용한다.Colchicine (used when the diagnosis is not clear), nonsteroidal antiinflammatory drugs (when there is no complication and diagnosis is confirmed but there is a high possibility of side effects such as peptic ulcer, renal dysfunction and edema), steroid Mainly used as intra-articular injection or intramuscular injection in single arthritis).
그러나 현대의학적으로 통풍을 근본적으로 치료하는 약은 개발되어 있지 않다. 다만, 항고요산제로 요산생성 저해제인 '알로퓨리놀(allopurinol)'과 요산 신장배설 촉진제인 '프로베네시드(probenecid)' 등이 있으나, 알로퓨리놀의 경우 피부발진, 위장장애, 골수저해, 가려움증, 구역질, 근육통 등과 같은 심각한 부작용이 있는 바, 안전하고 부작용이 적으면서 통풍을 예방하고 치료할 수 있는 물질의 발명이 요구되고 있다. 고요산혈증은 주로 40~50대 성인 남성에 자주 발생하며 요산 결정이 관절 내에 침착되어 급성 관절염을 유발하거나 골, 연골 및 연조직에 침착되어 요산결절을 형성하기도 하며, 요산결정이 비뇨기계에 침착될 경우 신결석이나 신병증을 유발하기도 한다. 고요산혈증이 지속되어 관절 내 요산결정이 침착되어 급작스러운 통증을 나타내는 것을 급성 통풍 발작이라 하며 이때부터 통풍 환자로 분류된다. 통풍의 치료에 있어서 급성 통풍성 관절염의 경우 통증과 염증을 경감시키고, 만성 통풍성 관절염의 경우 통풍결절을 감소시키고 급성 관절염의 발현을 억제하여 통풍의 원인이 되는 고요산혈증을 교정하는 것이 중요하다.However, modern medicines have not been developed to fundamentally treat gout. However, allopurinol, an inhibitor of uric acid uric acid production, and probenecid, a uric acid kidney excretion promoter, are known to cause skin eruption, gastrointestinal disorder, bone marrow inhibition, itching, nausea, , There is a demand for an invention of a substance which can prevent and treat gout while being safe and having few side effects. Hyperuricemia frequently occurs in men in their 40s and 50s, and uric acid crystals are deposited in the joints to cause acute arthritis, or to settle in bone, cartilage and soft tissues to form uric acid nodules. When uric acid crystals are deposited in the urinary system It may also cause kidney stones or nephropathy. Acute acute respiratory distress syndrome is characterized by the persistent accumulation of urate crystals in the joints, which are called acute gout attacks. In the treatment of gout, it is important to alleviate pain and inflammation in acute gouty arthritis, and to reduce gouty nodules in chronic gouty arthritis, and to suppress the expression of acute arthritis and correct hyperuricemia, which is the cause of gout.
고요산혈증의 원인을 살펴보면, 우리 몸을 구성하고 있는 대부분의 세포는 핵을 가지고 있는데, 이는 유전정보를 담고 있는 핵산으로 이루어져 있다. 핵산은 퓨린(purine)이나 피리미딘(pyrimidine)으로 구성되어 있고, 세포 수명이 다하면 파괴되어 핵 속의 퓨린체가 생체 내 대사과정을 거친다. 퓨린체의 대사과정 중 아데닌은 하이포잔틴(hypoxanthine)과 잔틴(xanthine)을 거쳐 요산으로 만들어지고, 구아닌(guanine)은 직접 잔틴으로 대사되어 요산으로 분해되는데, 이때 잔틴산화효소(xanthine oxidase)가 관여하는 것으로 알려져 있다. 잔틴산화효소가 잔틴을 요산으로 전환시킬 때 초과산화 라디칼(superoxide radical)을 대량 생성함으로써 주변 세포에 산화적 스트레스를 주어 통풍뿐만 아니라, 고혈압, 고지혈증, 동맥경화증, 당뇨병 등과 같은 동반질환을 수반하게 된다고 알려져 있다(Storch J et al., Anal.Biochem., 169: 262-267, 1988).As for the causes of hyperuricemia, most of the cells that make up our body have nuclei, which are made up of nucleic acids containing genetic information. The nucleic acid is composed of purine or pyrimidine. When the cell reaches its end of life, the nucleic acid is destroyed and the purine body in the nucleus undergoes metabolism in vivo. During the metabolic process of purines, adenine is made into uric acid via hypoxanthine and xanthine. Guanine is metabolized directly into xanthine and decomposed into uric acid. In this case, xanthine oxidase is involved . When xanthine oxidase converts xanthine to uric acid, it produces large amounts of superoxide radicals, which gives oxidative stress to the surrounding cells, accompanied by not only gout, but also accompanying diseases such as hypertension, hyperlipidemia, arteriosclerosis, diabetes and the like (Storch J et al., Anal. Biochem., 169: 262-267, 1988).
혈중 요산이 과도(7.0 mg/dL 이상)하게 존재할 경우 관절 주위로 몰려 날카로운 결정체를 형성하여 격렬한 통증을 유발시키는 질환을 통풍이라 한다. 현재 의약품 시장에는 알로푸리놀(allopurinol), 프로베네시드(probenecid), 콜치신(colchicine) 등이 알려져 있으나 약물에 다양한 부작용이 보고된 바 있다. 따라서 혈중 요산 수치를 보다 효과적으로 감소시킴과 동시에 장기간 안전하게 복용할 수 있는 신규 소재의 개발 필요성이 요구되어지고 있다.If the blood uric acid is present in excess (7.0 mg / dL or more), it forms a sharp crystal around the joints and causes severe pain. Currently, allopurinol, probenecid, colchicine, etc. are known in the pharmaceutical market, but various side effects have been reported in the drug. Therefore, there is a demand for the development of new materials that can reduce the uric acid level in blood more effectively and safely take it for a long period of time.
따라서 본 발명자는 혈중 요산 수치 감소능과 잔틴산화효소 저해능 등을 가지는 천연물소재에 대한 연구를 수행하였고, 가자 추출물 또는 이로부터 분리된 화합물의 상기 효과에 대한 검증을 통해 본 발명을 완성하였다.Accordingly, the present inventors have conducted studies on natural materials having the ability to reduce uric acid levels in blood and the ability to inhibit xanthine oxidase, and have completed the present invention by examining the above-mentioned effects of Gadja extract or compounds isolated therefrom.
본 발명의 목적은 가자 추출물 또는 이로부터 분리된 화합물의 혈 중 요산 감소에 따른 고요산혈증, 통풍 등의 질환 예방, 개선 및 치료효과를 나타내는 조성물을 제공하는데 있다.It is an object of the present invention to provide a composition for preventing, ameliorating and curative effect of Ghatti extract or compounds isolated therefrom, such as hyperlipidemia and gout due to decreased uric acid in blood.
상기 목적을 달성하기 위하여, 본 발명은 가자 추출물 및 분리된 화합물의 혈 중 요산수치 감소 효능 및 잔틴산화효소 억제능을 확인함으로써, 본 발명을 제공하고자 한다.In order to achieve the above object, the present invention provides the present invention by confirming the reducing effect of uric acid levels and the inhibitory activity of xanthine oxidase of Gadjat extract and isolated compounds.
본 발명은 가자 추출물을 유효성분으로 포함하는 고요산혈증 또는 통풍 예방 및 치료용 조성물에 대한 것이다. 가자를 물, 알코올 또는 에틸아세테이트로 추출할 수 있으며, 바람직하게는 물, 에탄올, 메탄올 또는 에틸아세테이트로 추출할 수 있다. The present invention relates to a composition for preventing and treating hyperuricemia or gout comprising an extract of Ghazale as an active ingredient. The extract may be extracted with water, alcohol or ethyl acetate, preferably with water, ethanol, methanol or ethyl acetate.
또한, 본 발명은 가자 추출물로부터 분리된 하기 화학식 1 및 2 중 어느 하나 이상의 화합물을 포함하는 고요산혈증 또는 통풍 예방 및 치료용 조성물에 대한 것이다.The present invention also relates to a composition for preventing and treating hyperuricemia or gout comprising at least one compound selected from the following formulas (1) and (2) isolated from Gadjat extract.
여기서, R1~R5은 갈릭산 또는 H 이다.Here, R 1 to R 5 are gallic acid or H.
여기서 R1~R3은 갈릭산 또는 H 이다.Wherein R < 1 > to R < 3 >
상기 화학식 1 및 2의 화합물을 분리하는 방법에서 어떠한 용매에 한정하지 않는다. 바람직하게는, 물, 탄소수 1 내지 4개의 저급 알코올 용매, 또는 10 내지 95% 저급 알코올 수용액으로 분리할 수 있다.The method of separating the compounds of the above formulas (1) and (2) is not limited to any solvent. Preferably, it can be separated into water, a lower alcohol solvent having 1 to 4 carbon atoms, or a 10 to 95% lower alcohol aqueous solution.
가자 추출물 또는 이로부터 분리된 화합물의 혈 중 요산 감소에 따른 고요산혈증, 통풍 등의 질환 예방, 개선 및 치료효과를 나타내는 조성물을 제공한다.The present invention provides a composition for preventing, ameliorating, and treating a disease caused by hypolipidemia, hypolipidemia, gout and the like caused by the reduction of uric acid in the blood of a Ghazu extract or a compound isolated therefrom.
이하, 본 발명을 하기의 실시예에 의하여 더욱 상세히 설명한다. 그러나 이들 실시예는 본 발명을 예시하기 위한 것일 뿐이며, 본 발명의 범위가 이들 실시예에 의하여 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to the following examples. However, these examples are only for illustrating the present invention, and the scope of the present invention is not limited by these examples.
가자 추출물 제조Manufacture of GAZA extract
건조된 가자 원생약 100 g을 정제수, 에탄올, 메탄올 및 에틸아세테이트 용매 1 L에 각각 침적시켜 3시간 동안 환류 추출하였다. 이에 얻어진 각 추출물은 여과 후 감압농축하고, 최종 동결건조를 실시하여 정제수 추출물 (63 g, 63.4%), 에탄올 추출물 (29 g, 29.2%), 메탄올 추출물 (61 g, 61.2%) 및 에틸아세테이트 추출물 (7 g, 7.4%)을 얻었다.100 g of the dried potato herb was immersed in 1 L of purified water, ethanol, methanol and ethyl acetate solvent, respectively, and refluxed for 3 hours. The extracts thus obtained were filtered, concentrated under reduced pressure, and finally lyophilized to give purified water extract (63 g, 63.4%), ethanol extract (29 g, 29.2%), methanol extract (61 g, 61.2%) and ethyl acetate extract (7 g, 7.4%).
가자 추출물에서의 유효성분 분리Isolation of Active Ingredients from Gaza Extract
㈜휴먼허브에서 구입한 가자 1.8 kg을 메탄올로 추출한 후 추출물을 진공 감압농축하여 메탄올 추출물 652 g을 얻었다. 상기 추출물을 물에 현탁한 후, 헥산, 클로로포름, 부탄올로 순차적으로 용매 분획하여 용매 분획물을 각각 3 g, 4 g, 350 g 수득하고 수용액층 295 g을 얻었다. 이중 부탄올 분획을 이온흡착수지 컬럼 크로마토그래피 (Diaion HP-20 column chromatography)를 이용하여 이동상 용매의 종류에 따라 4개의 분획으로 나누었다. 이중 1번째 분획을 다시 C18 역상 실리카겔(silica gel)을 고정상으로 아세토니트릴(acetonitrile)-물 혼합용매를 이동상으로 한 칼럼 크로마토그래피(column chromatography)를 실시하여 4개의 분획으로 나누었다. 1번째 분획에서 <화학식 2>의 화합물을, 4번째 분획에서 <화학식 1>의 화합물을 정제하였다.After 1.8 kg of GABA purchased from Human Hub Co., Ltd. was extracted with methanol, the extract was concentrated under reduced pressure to obtain 652 g of methanol extract. The above extract was suspended in water, followed by solvent fractionation with hexane, chloroform and butanol in order to obtain 3 g, 4 g and 350 g of solvent fractions, respectively, to obtain 295 g of an aqueous solution layer. The double butanol fraction was divided into four fractions according to the type of mobile phase solvent using ion adsorption resin column chromatography (Diaion HP-20 column chromatography). The first fraction was further subjected to column chromatography using a C18 reversed phase silica gel as a mobile phase with acetonitrile-water mixed solvent as a mobile phase, and then divided into four fractions. The compound of Formula 2 was purified from the first fraction and the compound of Formula 1 was purified from the fourth fraction.
<화학식 1>≪ Formula 1 >
<화학식 2>(2)
(G : (G: 갈릭산Garlic Mountain , H : 수소), H: hydrogen)
가자 추출물 Gaza extract 혈 중In blood 요산수치Uric acid level 측정 Measure
혈 중 요산수치 억제효능을 확인하기 위하여 유리케이즈(uricase) 저해제인 칼륨 옥소네이트(potassium oxonate)를 이용하여 고요산혈증을 유발하는 시험을 이용하였다. 시험동물로는 5주령의 Sprague-Dawley 랫트(Rat)를 이용하였다. 각 그룹당 10마리씩 체중이 균등하게 분배하여 상기 실시예 1의 조성물인 용매별 가자 추출물을 200 mg/kg의 농도로 경구 투여 한 후, 1시간 뒤 칼륨 옥소네이트 10 mg/kg를 복강투여하였다. 용매별 가자 추출물 투여 7시간째에 혈액을 채취하여 혈액생화학분석기를 이용하여 요산수치를 측정하였다. 대조약물로는 알로퓨리놀(allopurinol, 10 mg/kg)을 사용하였다. 그 결과를 하기 표 1에 나타내었다.Tests to induce hyperuricemia were made using potassium urate inhibitor potassium oxonate to confirm the inhibitory effect of uric acid levels in blood. Five-week-old Sprague-Dawley rats (Rats) were used as test animals. Each group was divided into 10 groups, and the composition of Example 1 was orally administered at a concentration of 200 mg / kg. Then, 10 mg / kg of potassium oxonate was administered intraperitoneally for 1 hour. Seven hours after the administration of the extracts of the solvent, the blood was collected and the uric acid level was measured using a blood biochemical analyzer. Allopurinol (10 mg / kg) was used as the reference drug. The results are shown in Table 1 below.
상기 표 1에서 확인할 수 있듯이, 용매별 가자 추출물의 혈 중 요산수치를 확인한 결과, 가자 물 추출물 및 에틸아세테이트 추출물에서 칼륨 옥소네이트로 유발시킨 유발군 대비 유의적(p<0.05)으로 요산수치를 감소시키는 것을 확인하였다.As shown in Table 1, the uric acid levels in the blood of the ghatti extracts of the solvent were significantly (p <0.05) lower than those of the potassium oxonate-induced groups in the water extract of Ghazam and ethyl acetate .
가자 물 추출물의 농도에 따른 Depending on the concentration of goat water extract 혈 중In blood 요산수치Uric acid level 측정 Measure
상기 실시예 3와 같은 방법으로 시험동물에서 혈 중 요산수치 억제효능을 확인하였다. 각 그룹당 10마리씩 체중이 균등하게 분배하여 가자 물 추출물을 50, 100, 200 및 400 mg/kg의 농도로 경구 투여 한 후 1시간 뒤 칼륨 옥소네이트 10 mg/kg를 복강투여하였다. 농도별 가자 물 추출물 투여 7시간째에 혈액을 채취하여 혈액생화학분석기를 이용하여 요산수치를 측정하였다. 대조약물로는 알로퓨리놀(allopurinol, 10 mg/kg)을 사용하였다. 그 결과를 하기 표 2에 나타내었다.In the same manner as in Example 3, the effect of inhibiting the uric acid level in blood was confirmed in the test animals. Each group was divided into 10 groups and the water extracts were orally administered at a concentration of 50, 100, 200 and 400 mg / kg. After 1 hour, 10 mg / kg of potassium oxonate was intraperitoneally administered. Seven hours after administration of the water extract of Gamja at different concentrations, blood was collected and uric acid levels were measured using a blood biochemical analyzer. Allopurinol (10 mg / kg) was used as the reference drug. The results are shown in Table 2 below.
상기 표 2에서 확인할 수 있듯이, 농도별 가자 물 추출물의 혈 중 요산수치를 확인한 결과, 농도의존적으로 혈 중 요산수치를 감소시키는 것을 확인할 수 있었다. 특히, 가자 물 추출물 200 과 400 mg/kg에서 칼륨 옥소네이트로 유발시킨 유발군 대비 유의적(p<0.05)으로 요산수치를 감소시키는 것을 확인하였다.As shown in the above Table 2, the uric acid level in the blood of the Gamma water extract according to the concentration was confirmed, and it was confirmed that the uric acid level in the blood was decreased depending on the concentration. Especially, it was confirmed that the uric acid level was decreased by significantly (p <0.05) compared with the induction group induced by potassium oxonate at 200 and 400 mg / kg of the water extract of Ganoderma lucidum.
가자추출물Gaza extract 및 유효성분의 And of the active ingredient 잔틴산화효소Xanthine oxidase 저해 효과 Inhibitory effect
상기 실시예 1을 통해 제조한 가자 물 추출물과 실시예 2를 통해 분리된 화합물의 잔틴산화효소 억제능 평가를 위하여, Prajda and Weber’s method를 이용하여 평가하였다(Prajda N et al., FEBS Lett., 59: 245-249, 1975). 실험은 96 웰 플레이트에 PBS 버퍼(0.2 M, 0.1 mM EDTA)에 녹인 가자 농도 별 추출물 시료용액 20 μL을 분주하고, 효소액으로 PBS 버퍼에 10 mU/mL로 녹인 잔틴 산화효소를 90 μL 첨가한 후 37℃에서 10분간 배양 한 뒤 기질액인 0.1 mM의 잔틴 90 μL를 첨가했다. 다시 10분간 배양한 뒤 반응을 종료하고 290 nm에서 흡광도를 측정하였다. 모든 실험은 3번 반복 수행하였고, 잔틴산화효소 억제능(%)은 다음 식에 의하여 구하였다.The evaluation of the inhibitory activity of xanthine oxidase by the extract prepared from Example 1 and the compound isolated through Example 2 was evaluated using the Prajda and Weber's method (Prajda N et al., FEBS Lett., 59 : 245-249, 1975). 20 μL of sample solution was added to 96-well plate in PBS buffer (0.2 M, 0.1 mM EDTA), and 90 μL of xanthine oxidase dissolved in PBS buffer was added to PBS buffer After incubating at 37 ° C for 10 minutes, 90 μL of 0.1 mM xanthan, a substrate solution, was added. After incubation for another 10 minutes, the reaction was terminated and absorbance was measured at 290 nm. All experiments were repeated 3 times, and the inhibitory activity of xanthine oxidase (%) was determined by the following equation.
A : 기질액에 시료와 효소액을 첨가하여 반응시킨 후의 흡광도A: Absorbance after reaction with sample and enzyme solution in substrate solution
B : A에서 효소액 대신 PBS를 첨가하여 반응시킨 후의 흡광도B: Absorbance after reaction by adding PBS instead of enzyme solution in A
C : A에서 시료 대신 PBS를 첨가하여 반응시킨 후의 흡광도C: Absorbance after reaction by adding PBS instead of the sample in A
그 결과를 하기 표 3에 나타내었다.The results are shown in Table 3 below.
(IC50, μg/mL)Xanthine oxidase inhibitory ability
(IC 50 , μg / mL)
(Allopurinol)Alopurinol
(Allopurinol)
상기 표 3에서 확인할 수 있듯이, 가자 물 추출물과 가자로부터 분리된 화합물의 잔틴산화효소 억제능을 확인한 결과, 분리된 화합물에서 높은 잔틴산화효소 억제능을 확인할 수 있었다. As shown in Table 3, the ability of the extracts of Ghatti extract and the compounds isolated from Ghazi to inhibit xanthine oxidase was confirmed.
Claims (5)
<화학식 1>
R1~R5은 갈릭산(Gallic acid) 또는 H 이고,
<화학식 2>
R1~R3은 갈릭산(Gallic acid) 또는 H 임.Compositions for preventing or treating hyperuricemia or gout comprising at least one compound selected from the following formulas (1) and (2) isolated from Gadja extract:
≪ Formula 1 >
R 1 to R 5 are gallic acid or H,
(2)
R 1 to R 3 are gallic acid or H;
5. The composition of claim 4, comprising a compound isolated from water extract, lower alcohol having 1 to 4 carbon atoms, or 10 to 95% lower alcohol aqueous solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160062829A KR20170131963A (en) | 2016-05-23 | 2016-05-23 | A composition comprising extracts of Terminalia chebula or compounds isolated from the above extracts for decreasing uric acid concentration in blood |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160062829A KR20170131963A (en) | 2016-05-23 | 2016-05-23 | A composition comprising extracts of Terminalia chebula or compounds isolated from the above extracts for decreasing uric acid concentration in blood |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20170131963A true KR20170131963A (en) | 2017-12-01 |
Family
ID=60921760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160062829A KR20170131963A (en) | 2016-05-23 | 2016-05-23 | A composition comprising extracts of Terminalia chebula or compounds isolated from the above extracts for decreasing uric acid concentration in blood |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20170131963A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115518089A (en) * | 2022-09-20 | 2022-12-27 | 广东药科大学 | Preparation method and application of myrobalan submicron powder |
| CN115554325A (en) * | 2022-09-21 | 2023-01-03 | 国药集团健康产业研究院有限公司 | Application of medicine terminalia fruit, extractive or preparation thereof in preparing anti-inflammatory, analgesic or uric acid-reducing medicines |
-
2016
- 2016-05-23 KR KR1020160062829A patent/KR20170131963A/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115518089A (en) * | 2022-09-20 | 2022-12-27 | 广东药科大学 | Preparation method and application of myrobalan submicron powder |
| CN115554325A (en) * | 2022-09-21 | 2023-01-03 | 国药集团健康产业研究院有限公司 | Application of medicine terminalia fruit, extractive or preparation thereof in preparing anti-inflammatory, analgesic or uric acid-reducing medicines |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pari et al. | Efficacy of coumarin on hepatic key enzymes of glucose metabolism in chemical induced type 2 diabetic rats | |
| Kang et al. | Resveratrol improves insulin signaling in a tissue-specific manner under insulin-resistant conditions only: in vitro and in vivo experiments in rodents | |
| RU2663127C2 (en) | Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction | |
| US20090042951A1 (en) | Blood Pressure Reduction in Salt-Sensitive Hypertension | |
| JP2009501696A (en) | Insulin resistance treatment | |
| EP0319463A2 (en) | Use of 4H-benzo[4,5]cyclohepta[1,2-b]thiophene derivatives to effect monokine inhibition | |
| US20130040006A1 (en) | Extracts of Eleutherococcus SPP., Preparation Method Thereof and Use of the Same | |
| KR20100060279A (en) | Composition for ameliorating the er stress or the mitochondrial dysfunction comprising the extract of angelica dahurica or imperatorin | |
| Bao et al. | Eurycomanol alleviates hyperuricemia by promoting uric acid excretion and reducing purine synthesis | |
| KR20170131963A (en) | A composition comprising extracts of Terminalia chebula or compounds isolated from the above extracts for decreasing uric acid concentration in blood | |
| Wang et al. | Curcumin analog JM-2 alleviates diabetic cardiomyopathy inflammation and remodeling by inhibiting the NF-κB pathway | |
| CN111356468A (en) | Composition for preventing or treating fibrotic disease comprising extract of Rhus toxicodendron | |
| US20110262567A1 (en) | Composition for treating gout, containing angelica gigas extract having a xanthine oxidase-inhibiting effect and an inflammation-inducing enzyme-inhibiting effect | |
| CN109550051B (en) | Application of histone demethylase KDM6A inhibitor in preparation of obesity treatment drug | |
| KR101760565B1 (en) | Pharmaceutical composition for preventing or treating diabetic muscle atrophy comprising the activity inhibitor of tenc1 | |
| KR101074555B1 (en) | The preparing method of extracts of momordica charantia for treating gout and the extracts prepared thereof | |
| JP6441364B2 (en) | Weight gain control using dibenzo-alpha-pyrone | |
| US8273388B2 (en) | Extract of Polygonum multiflorum Thunb. ex Murray var. hypoleucum and compositions for improving metabolic syndrome | |
| Waldenlind et al. | Effect of peroral thiamine treatment on thiamine contents and transketolase activity of red blood cells in alcoholic patients | |
| CN111956751A (en) | Pharmaceutical composition for treating hyperuricemia and preparation method thereof | |
| JP2657614B2 (en) | Aromatase inhibitor | |
| CN115177662B (en) | Application of waistcoat or its extract in preparing medicine for treating gout | |
| KR100783204B1 (en) | A composition for inhibiting obesity and hyperlipidemia | |
| US9226950B2 (en) | Method and composition for treating diabetes mellitus | |
| KR20060025693A (en) | Composition comprising betaine as an effective component using as an anti-oxidant, anti-aging or anti-inflammatory agent |